Status:
COMPLETED
Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects
Lead Sponsor:
Imperial College London
Conditions:
Asthma
Eligibility:
All Genders
21-60 years
Phase:
NA
Brief Summary
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in ex...
Detailed Description
Nitric oxide (NO) is produced by a variety of cells within the respiratory tract, particularly airway epithelial cells, and its increased concentration in asthma is likely to derive from inducible NO ...
Eligibility Criteria
Inclusion
- Healthy non-smokers (n=10):
- Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s)
- Normal spirometry
- Able to comprehend and grant a written informed consent
- Asthmatic subjects (n=15):
- Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s)
- Clinically stable (steroid-naïve or taking no \> 600 mcg/day of inhaled steroids)
- Able to comprehend and grant a written informed consent
Exclusion
- Currently smoking
- Any lung disease other than asthma which may interfere with the study
- Treatment within the last 4 weeks with oral steroids
- Respiratory infection within 4 weeks prior to entry into the trial
- Females who are pregnant or lactating
- History of current or past drug or alcohol abuse
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00159380
Start Date
September 1 2003
End Date
March 1 2005
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY